# EDGAR Filing Document

**Accession Number:** 0002027329
**File Stem:** 0001193125-26-166745
**Filing Date:** 2026-4
**Character Count:** 19775
**Document Hash:** 14b9142bb7a00aa9204e51c1c021d2e1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-166745.hdr.sgml**: 20260421

**ACCESSION NUMBER**: 0001193125-26-166745

**CONFORMED SUBMISSION TYPE**: F-1/A

**PUBLIC DOCUMENT COUNT**: 11

**FILED AS OF DATE**: 20260421

**DATE AS OF CHANGE**: 20260421

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Optimi Health Corp.
- **CENTRAL INDEX KEY:** 0002027329
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** F-1/A
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-290086
- **FILM NUMBER:** 26879433

**BUSINESS ADDRESS:**
- **STREET 1:** UNIT 600, 21 WATER STREET
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6B 1A1
- **BUSINESS PHONE:** 6043770403

**MAIL ADDRESS:**
- **STREET 1:** UNIT 600, 21 WATER STREET
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6B 1A1

**As filed with the U.S. Securities and Exchange Commission on April 21, 2026.** 

**Registration No. 333-290086** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, D.C. 20549** 

**AMENDMENT NO. 6** 

**TO** 

**FORM F-1** 

**REGISTRATION STATEMENT** 

**UNDER** 

**THE SECURITIES ACT OF 1933** 

## OPTIMI HEALTH CORP.
**(Exact name of Registrant as specified in its charter)** 

**Not Applicable** 

**(Translation of Registrant's Name into English)** 

---

| | | |
|:---|:---|:---|
| **British Columbia** | **2834** | **Not Applicable** |
| **(State or other jurisdiction of<br>incorporation or organization)** | **(Primary Standard Industrial<br>Classification Code Number)** | **(I.R.S. Employer<br>Identification No.)** |

---

**269 David Brown Way** 

**Princeton, B.C. V0X 1W0** 

**Canada** 

(**778) 761-4551** 

**(Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices)** 

**Cogency Global Inc.** 

**122 East 42nd Street, 18th Floor New York, NY 10168** 

**(800) 221-0102** 

**(Names, address, including zip code, and telephone number, including area code, of agent for service)** 

***Copies to:***

---

| | | |
|:---|:---|:---|
| **Kevin Friedmann, Esq.**<br> **Siyuan An, Esq.**<br> **Norton Rose Fulbright US LLP**<br> **1045 W. Fulton Market, Suite 1200**<br> **Chicago, IL 60607**<br> **(312) 964-7763** | **Kristopher Miks, Esq.**<br> **Norton Rose Fulbright Canada LLP**<br> **510 West Georgia Street, Suite 1800 Vancouver, B.C. V6B 0M3, Canada**<br> **(604) 687-6575** | **Kevin Roggow, Esq.**<br> **Cozen O'Connor**<br> **3 World Trade Center**<br> **175 Greenwich Street, 55th Floor**<br> **New York, NY 10007**<br> **(212) 908-1294** |

---

**Approximate date of commencement of proposed sale to the public:** As soon as practicable after the effective date of this registration statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement the same offering. ☐

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.

Emerging growth company ☒

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

† The term "new or revised financial accounting standard" refers to any update issued by the Financial
Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

**The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act or until the registration statement shall become effective on such date as the U.S. Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.** 

------

**Explanatory Note** 

This Amendment No. 6 (this "Amendment") to the Registration Statement on Form F-1 (No. 333-290086) (the "Registration Statement") is being filed as an exhibit-only filing to file an amended Filing Fee Table, filed herewith as Exhibit 107. Accordingly, this Amendment consists only of the facing page, this explanatory note, Item 8 of Part II of the Registration Statement, the signature page to the Registration Statement and Exhibit 107. The prospectus and the balance of Part II of the Registration Statement are unchanged and have been omitted.

**Item 8. Exhibits and Financial Statement Schedules.** 

(a) Exhibits

See Exhibit Index for a complete list of all exhibits filed as part of this Registration Statement, which Exhibit Index is incorporated herein by reference.

(b) Financial Statement Schedules

Schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or the notes thereto.

------

**EXHIBIT INDEX** 

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 1.1\*\* | [Form of Underwriting Agreement](http://www.sec.gov/Archives/edgar/data/2027329/000119312526165337/d43258dex11.htm) |
| 3.1\*\* | [Notice of Articles](http://www.sec.gov/Archives/edgar/data/2027329/000119312525197327/d81568dex31.htm) |
| 3.2\*\* | [Articles](http://www.sec.gov/Archives/edgar/data/2027329/000119312525197327/d81568dex32.htm) |
| 4.1\*\* | [Form of Underwriter Warrant](http://www.sec.gov/Archives/edgar/data/2027329/000119312526106121/d43258dex41.htm) |
| 5.1\*\* | [Opinion of Norton Rose Fulbright Canada LLP regarding the validity of the common shares being registered](http://www.sec.gov/Archives/edgar/data/2027329/000119312526165337/d43258dex51.htm) |
| 5.2\*\* | [Opinion of Norton Rose Fulbright US LLP regarding the enforceability of the Underwriter Warrants being registered](http://www.sec.gov/Archives/edgar/data/2027329/000119312526106121/d43258dex52.htm) |
| 10.1\*\* | [2020 Equity Incentive Plan](http://www.sec.gov/Archives/edgar/data/2027329/000119312525197327/d81568dex101.htm) |
| 10.2†\*\* | [Amended and Restated Industrial Lease Agreement dated as of September 1, 2021, entered into by and between the Company and BC Green Pharmaceuticals Inc.](http://www.sec.gov/Archives/edgar/data/2027329/000119312525197327/d81568dex102.htm) |
| 10.3\*\* | [First Amendment to Amended and Restated Industrial Lease Agreement dated as of July 1, 2025, entered into by and between the Company and BC Green Pharmaceuticals Inc.](http://www.sec.gov/Archives/edgar/data/2027329/000119312525197327/d81568dex103.htm) |
| 10.4†\*\* | [Loan Agreement dated as of August 4, 2023 entered into by and between the Company and Catcher Investments Limited](http://www.sec.gov/Archives/edgar/data/2027329/000119312525197327/d81568dex104.htm) |
| 10.5†\*\* | [General Security Agreement dated as of August 4, 2023 entered into by and between the Company and Catcher Investments Limited](http://www.sec.gov/Archives/edgar/data/2027329/000119312525197327/d81568dex105.htm) |
| 10.6†\*\* | [Loan Agreement dated August 29, 2023 entered into by and between the Company and 0959856 B.C. Ltd.](http://www.sec.gov/Archives/edgar/data/2027329/000119312525197327/d81568dex106.htm) |
| 10.7†\*\* | [General Security Agreement dated August 29, 2023 entered into by and between the Company and 0959856 B.C. Ltd.](http://www.sec.gov/Archives/edgar/data/2027329/000119312525197327/d81568dex107.htm) |
| 10.8†\*\* | [Loan Agreement dated August 29, 2023 entered into by and between the Company and Westward Visions Ltd.](http://www.sec.gov/Archives/edgar/data/2027329/000119312525197327/d81568dex108.htm) |
| 10.9†\*\* | [General Security Agreement dated August 29, 2023 entered into by and between the Company and Westward Visions Ltd.](http://www.sec.gov/Archives/edgar/data/2027329/000119312525197327/d81568dex109.htm) |
| 10.10†\*\* | [Loan Agreement dated November 1, 2023 entered into by and between the Company and Kerris Holdings Ltd.](http://www.sec.gov/Archives/edgar/data/2027329/000119312525197327/d81568dex1010.htm) |
| 10.11†\*\* | [General Security Agreement dated November 1, 2023 entered into by and between the Company and Kerris Holdings Ltd.](http://www.sec.gov/Archives/edgar/data/2027329/000119312525197327/d81568dex1011.htm) |
| 10.12\*\* | [Loan Agreement Amendment No.1 dated July 16, 2025 entered into by and between the Company and Kerris Holdings Ltd.](http://www.sec.gov/Archives/edgar/data/2027329/000119312525197327/d81568dex1012.htm) |
| 10.13†\*\* | [Purchase Agreement dated as of February 28, 2023 entered into by and among the Company, KMT Pharmaceuticals Pty Ltd and Mind Medicine Australia Limited](http://www.sec.gov/Archives/edgar/data/2027329/000119312525197327/d81568dex1013.htm) |
| 16.1\*\* | [Letter from Smythe LLP](http://www.sec.gov/Archives/edgar/data/2027329/000119312525197327/d81568dex161.htm) |
| 21.1\*\* | [Principal Subsidiaries of the Registrant](http://www.sec.gov/Archives/edgar/data/2027329/000119312525197327/d81568dex211.htm) |
| 23.1\*\* | [Consent of Davidson & Company LLP, an independent registered public accounting firm](http://www.sec.gov/Archives/edgar/data/2027329/000119312526165337/d43258dex231.htm) |
| 23.2\*\* | [Consent of Norton Rose Fulbright Canada LLP (included in Exhibit 5.1)](http://www.sec.gov/Archives/edgar/data/2027329/000119312526165337/d43258dex51.htm) |

---

------

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 23.3\*\* | [Consent of Norton Rose Fulbright US LLP (included in Exhibit 5.2)](http://www.sec.gov/Archives/edgar/data/2027329/000119312526106121/d43258dex52.htm) |
| 24.1\*\* | [Powers of Attorney (included on signature page)](http://www.sec.gov/Archives/edgar/data/2027329/000119312525197327/d81568df1.htm#sig) |
| 99.1\*\* | [Code of Business Conduct and Ethics of the Registrant](http://www.sec.gov/Archives/edgar/data/2027329/000119312525197327/d81568dex991.htm) |
| 107 | [Filing Fee Table](d43258dexfilingfees.htm) |

---

\* To be filed by amendment

\*\* Previously filed

† Certain portions of this exhibit have been omitted because it is both not material and is the type that the
registrant treats as private or confidential

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-1 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Vancouver, British Columbia, on April 21, 2026.

---

| | |
|:---|:---|
| **Optimi Health Corp.** | **Optimi Health Corp.** |
| By: | /s/ Dane Stevens |
| Name: | Dane Stevens |
| Title: | Chief Executive Officer, Chief Marketing Officer and Director |

---

------

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons on April 21, 2026 in the capacities indicated.

---

| | |
|:---|:---|
| **Signature** | **Title** |
| /s/ Dave Stevens | Chief Executive Officer, Chief Marketing Officer and Director (principal executive officer) |
| Dane Stevens |  |
| \* | Interim Chief Financial Officer and Director (principal financial and accounting officer) |
| Jacob Safarik |  |
| \* | Chief Operating Officer and Director |
| Bryan Safarik |  |
| \* | Chairman and Director |
| John James Wilson |  |
| \* | Director |
| Jason Mosberian |  |

---

---

| | |
|:---|:---|
| \*By: | /s/ Dave Stevens |
| Name: | Dane Stevens |
| Title: | Attorney-in-fact |

---

------

**SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES** 

Pursuant to the Securities Act of 1933, the undersigned, the duly authorized representative in the United States of Optimi Health Corp. has signed this registration statement or amendment thereto in New York on April 21, 2026.

---

| | |
|:---|:---|
| Authorized U.S. Representative | Authorized U.S. Representative |
| By: | /s/ Colleen A. De Vries |
| Name: | Colleen A. De Vries |
| Title: | Sr. Vice President on behalf of Cogency Global Inc. |

---

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**F-1**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Optimi Health Corp.**  |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | | **Security Type**  | **Security Class Title**  | **Fee Calculation or Carry Forward Rule**  | **Maximum Aggregate Offering Price**  | **Amount of Registration Fee**  |
| **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** |
| Fees to be Paid |  |  |  |  |  |  |
| Fees Previously Paid | 1 | Equity | common shares, no par value | 457(o) | $17250000.00 | $2382.22 |
| Fees Previously Paid | 2 | Equity | warrants to be issued to the underwriter | Other |  | $0.00 |
| Fees Previously Paid | 3 | Equity | common shares, no par value, underlying warrants to be issued to the underwriter | 457(o) | $1035000.00 | $142.93 |
| Fees Previously Paid | 4 | Equity | common shares, no par value, underlying common warrants | 457(o) | $20700000.00 | $2858.67 |
| **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** |
| Carry Forward Securities |  |  |  |  |  |  |
|  |  |  | Total Offering Amounts: | Total Offering Amounts: | $38985000.00  | $5383.82  |
|  |  |  | Total Fees Previously Paid:  | Total Fees Previously Paid:  |  | $5383.82  |
|  |  |  | Total Fee Offsets:  | Total Fee Offsets:  |  | $0.00  |
|  |  |  | Net Fee Due:  | Net Fee Due:  |  | $0.00  |

---

 **Offering Note** <br>

<sup>1</sup> (1) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), there are also being registered hereby such indeterminate number of additional securities as may be issued or issuable to prevent dilution resulting from share splits, share dividends or similar transactions. (2) Includes (a) common shares that may be purchased by the underwriter pursuant to its over-allotment option and (b) all common shares initially offered and sold outside the United States that may be resold from time to time in the United States either as part of the distribution or within 40 days after the later of the effective date of this registration statement and the date the securities are first bona fide offered to the public. (3) Maximum aggregate offering price estimated solely for the purpose of determining the amount of registration fee in accordance with Rule 457(o) under the Securities Act. The registrant previously paid a fee of $5,383.82 related to the maximum aggregate offering price of units, which is no longer applicable, and which is applied to the registrant's total registration fee of $2,525.15.

<sup>2</sup> (1) Pursuant to Rule 416 under the Securities Act, there are also being registered hereby such indeterminate number of additional securities as may be issued or issuable to prevent dilution resulting from share splits, share dividends or similar transactions. (2) The registrant has agreed to issue to Joseph Gunnar & Co., LLC warrants (the "Underwriter Warrants") to purchase a number of common shares equal to an aggregate of 5% of the total number of common shares sold in this offering, including any common shares sold pursuant to the underwriter's option to purchase additional common shares. Resales of the Underwriter Warrants on a delayed or continuous basis pursuant to Rule 415 under the Securities Act, are registered hereby. Resales of common shares issuable upon exercise of the Underwriter Warrants are also being similarly registered on a delayed or continuous basis hereby. As estimated solely for the purpose of recalculating the registration fee pursuant to Rule 457(g) under the Securities Act, the proposed maximum aggregate offering price of the Underwriter Warrants is $1,035,000 which is equal to 120% of $862,500 (5% of $17,250,000). (3) The Underwriter Warrants are exercisable at a price per common share equal to 120% of the public offering price per common share. The Underwriter Warrants will be exercisable commencing six months after the closing of this offering and will expire five years from the commencement of sales in this offering. (4) No registration fee required pursuant to Rule 457(g) under the Securities Act.

<sup>3</sup> (1) Pursuant to Rule 416 under the Securities Act, there are also being registered hereby such indeterminate number of additional securities as may be issued or issuable to prevent dilution resulting from share splits, share dividends or similar transactions. (2) The registrant has agreed to issue to Joseph Gunnar & Co., LLC the "Underwriter Warrants" to purchase a number of common shares equal to an aggregate of 5% of the total number of common shares sold in this offering, including any common shares sold pursuant to the underwriter's option to purchase additional common shares. Resales of the Underwriter Warrants on a delayed or continuous basis pursuant to Rule 415 under the Securities Act, are registered hereby. Resales of common shares issuable upon exercise of the Underwriter Warrants are also being similarly registered on a delayed or continuous basis hereby. As estimated solely for the purpose of recalculating the registration fee pursuant to Rule 457(g) under the Securities Act, the proposed maximum aggregate offering price of the Underwriter Warrants is $1,035,000 which is equal to 120% of $862,500 (5% of $17,250,000). (3) Maximum aggregate offering price estimated solely for the purpose of determining the amount of registration fee in accordance with Rule 457(o) under the Securities Act. The registrant previously paid a fee of $5,383.82 related to the maximum aggregate offering price of units, which is no longer applicable, and which is applied to the registrant's total registration fee $2,525.15.

<sup>4</sup> (1) This is no longer applicable. The registrant previously paid a fee related to the maximum aggregate offering price of units, which is no longer applicable, and which is applied to the registrant's total registration fee.

---

| |
|:---|
| |
| **Rules 457(b) and 0-11(a)(2)** |
| Fee Offset Claims |
| Fee Offset Sources |
| **Rule 457(p)** |
| Fee Offset Claims |
| Fee Offset Sources |

---